


# **TOXICOLOGY IN VITRO**

Official Journal of the European Society of Toxicology in Vitro

#### AUTHOR INFORMATION PACK

## **TABLE OF CONTENTS**

•	Description	p.1
•	Audience	p.2
•	Impact Factor	p.2
•	Abstracting and Indexing	p.2
•	Editorial Board	p.2
•	Guide for Authors	p.4



ISSN: 0887-2333

#### DESCRIPTION

Toxicology in Vitro publishes original research papers and reviews on the application and use of in vitro systems for assessing or predicting the toxic effects of chemicals and elucidating their mechanisms of action. These in vitro techniques include utilizing cell or tissue cultures, isolated cells, tissue slices, subcellular fractions, transgenic cell cultures, and cells from transgenic organisms, as well as *in silico* modelling. The Journal will focus on investigations that involve the development and validation of new in vitro methods, e.g. for prediction of toxic effects based on traditional and in silico modelling; on the use of methods in high-throughput toxicology and pharmacology; elucidation of mechanisms of toxic action; the application of genomics, transcriptomics and **proteomics** in toxicology, as well as on comparative studies that characterise the relationship between in vitro and in vivo findings. The Journal strongly encourages the submission of manuscripts that focus on the development of in vitro methods, their practical applications and regulatory use (e.g. in the areas of food components cosmetics, pharmaceuticals, pesticides, and industrial chemicals). Toxicology in Vitro discourages papers that record reporting on toxicological effects from materials, such as plant extracts or herbal medicines, that have not been chemically characterized.

NEW! Special rate for ESTIV members now available. For more information contact Dr. Maria Laura Scarino

National Research Institute on Food and Nutrition (INRAN)

00178 Rome, Italy Tel: +39 06 51494497 Fax: +39 06 51 494550

Via Ardeatina 546

E-mail: scarino@inran.it

or visit the ESTIV website at http://www.estiv.org/

#### **Benefits to authors**

We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.

Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

#### **AUDIENCE**

Academic, governmental and industrial laboratories using in vitro techniques.

## **IMPACT FACTOR**

2013: 3.207 © Thomson Reuters Journal Citation Reports 2014

## ABSTRACTING AND INDEXING

**BIOSIS** 

Elsevier BIOBASE

Chemical Abstracts

Current Contents/BIOMED Database

Current Contents/Life Sciences

Current Contents/SciSearch Database

Current Contents/Science Citation Index

**EMBASE** 

Research Alert

Toxicology Abstracts

Scopus

**EMBiology** 

## **EDITORIAL BOARD**

#### **Editors**

**Daniel Acosta**, Deputy Director for Research, National Center for Toxicological Research (U.S. Food & Drug Administration), 3900 NCTR Road, Jefferson, AR 72079, USA

Frank A. Barile, Professor of Clinical & Applied Toxicology, Department of Pharmaceutical Sciences, St. John's University College of Pharmacy, 8000 Utopia Parkway, Queens, NY 11439, USA

Bas J. Blaauboer, Inst. for Risk Assessment Sciences (IRAS), Utrecht University, P.O. Box 80177, 3508 TD, Utrecht, Netherlands

## Associate Editor

**Kerstin Stemmer**, Institute for Diabetes and Obesity (IDO), Division of Metabolism and Cancer, Helmholtz Centre Munich, Business Campus Garching, Parkring 13, 85748 Garching, Germany

## International Editorial Board

A. Baeza-Squiban, Université Paris Diderot (Paris 7), Paris, France

M.D. Barratt, Marlin Consultancy, Bedford, England, UK

R.L. Bronaugh, Food and Drug Administration (FDA), College Park, Maryland, USA

G. Bánfalvi, University of Debrecen, Debrecen, Hungary

R.D. Combes, Norfolk, UK

G. Dal Negro, GlaxoSmithKline, Verona, Italy

J. Davila, University of Puerto Rico School of Medicine, San Juan, Puerto Rico

G.L. DeGeorge, MB Research Labs, Spinnerstown, Pennsylvania, USA

M. Ehrich, Virginia Polytechnic Institute & State University, Blacksburg, Virginia, USA

J. Fry, Queen's Medical Centre, Nottingham, England, UK

M.B. Genter, University of Cincinnati, Cincinnati, Ohio, USA

M. Goldoni, Università degli Studi di Parma, Parma, Italy

M.H. Grant, University of Strathclyde, Glasgow, Scotland, UK

R.L. Grant, Texas Commission on Environmental Quality, Austin, Texas, USA

S.G. Grant, University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA

A. Gray, Thor Personal Care SAS, Compiègne Cedex, France

G. Groothius, Rijksuniversiteit Groningen, Groningen, Netherlands

G.J.M.J. Horbach, N.V. Organon, Oss, Netherlands

P. Jennings, Medical University of Innsbruck, Innsbruck, Austria

I. Kimber, University of Manchester, Manchester, England, UK

A. Mally, Julius-Maximilians-Universität Würzburg, Würzburg, Germany

J.E. Manautou, University of Connecticut, Storrs, Connecticut, USA

M. Marinovich, Università degli Studi di Milano, Milano, Italy

R. Melchert, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

- N.A. Monteiro-Riviere, Kansas State University, Manhattan, Kansas, USA
- **D. Morgan**, National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, North Carolina, USA
- M. Murias, Poznan University of Medical Sciences, Poznan, Poland
- M. Nagao, National Cancer Center Research Institute, Tokyo, Japan
- A. Natsch, Givaudan Scweiz AG, Dübendorf, Switzerland
- A.K. Nüssler, Technische Universität München, München, Germany
- J.E. O'Connor, Universitat de València, Valencia, Spain
- L. G. Ocañas, Universidad Autónoma de Nuevo León, Garza Garcia, Nuevo León, Mexico
- A. Puga, University of Cincinnati, Cincinnati, Ohio, USA
- I.M.C.M. Rietjens, Wageningen Universiteit, Wageningen, Netherlands
- R. Rodriguez Proteau, Oregon State University, Corvalis, Oregon, USA
- H. Seibert, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
- A.C. Skladanowski, Medical University of Gdansk, Gdansk, Poland
- M.A. Sogorb, Universidad Miguel Hernández de Elche, Elche, Spain
- E. Testai, Istituto Superiore di Sanità, Roma, Italy
- C. Urani, Università degli Studi di Milano-Bicocca, Milano, Italy
- J. van Benthem, Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Bilthoven, Netherlands
- B. van der Burg, BioDetection Systems BV (BDS), Amsterdam, Netherlands
- M. Vinken, Vrije Universiteit Brussel (VUB), Brussels, Belgium
- R.H.S. Westerink, Utrecht University, Utrecht, Netherlands

## **GUIDE FOR AUTHORS**

## Your Paper Your Way

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

To find out more, please visit the Preparation section below.

## INTRODUCTION

# Types of paper

The Journal's main purpose will be the publication of papers reporting and interpreting original toxicological research involving the application or development of in vitro techniques. Brief Communications (2,500 word limit) documenting important new findings warranting expeditious publication will also be considered, as will concise interpretative Reviews of toxicological topics of contemporary significance. Letters to the Editor will be limited to comments on contributions already published in the Journal; if a letter is accepted, a response (for simultaneous publication) will be invited from the authors of the original contribution. *Toxicology in Vitro* also welcomes Correspondence from the scientific community, especially as they relate to Hot Topics and Debates. These are handled directly by the Editor-in-Chief and may be accompanied by responses.

#### **BEFORE YOU BEGIN**

# Ethics in publishing

For information on Ethics in publishing and Ethical guidelines for journal publication see <a href="http://www.elsevier.com/publishingethics">http://www.elsevier.com/publishingethics</a> and <a href="http://www.elsevier.com/journal-authors/ethics">http://www.elsevier.com/journal-authors/ethics</a>.

#### **Conflict of Interest**

Toxicology in Vitro follows the ICMJE recommendations regarding conflict of interest disclosures. All authors are required to report the following information with each submission: All third-party financial support for the work in the submitted manuscript. All financial relationships with any entities that could be viewed as relevant to the general area of the submitted manuscript. All sources of revenue with relevance to the submitted work who made payments to you, or to your institution on your behalf, in the 36 months prior to submission. Any other interactions with the sponsor of outside of the submitted work should also be reported. Any relevant patents or copyrights (planned, pending, or issued). Any other relationships or affiliations that may be perceived by readers to have influenced, or give the appearance of potentially influencing, what you wrote in the submitted work.

As a general guideline, it is usually better to disclose a relationship than not. This information will be acknowledged at publication in a Transparency Document. Additional information on the ICMJE recommendations can be found at: <a href="http://www.icmje.org">http://www.icmje.org</a>. The form for conflict of interest disclosure can be downloaded here, or at <a href="http://www.icmje.org/coi\_disclosure.pdf">http://www.icmje.org/coi\_disclosure.pdf</a> (if this link does not display properly in your browser, please right-click the link and select "Save Target As..." or "Save Link as..." from the popup menu.)

# Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <a href="http://www.elsevier.com/postingpolicy">http://www.elsevier.com/postingpolicy</a>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <a href="http://www.elsevier.com/editors/plagdetect">http://www.elsevier.com/editors/plagdetect</a>.

## Changes to authorship

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that

they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

# Copyright

This journal offers authors a choice in publishing their research: Open access and Subscription.

## For subscription articles

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <a href="http://www.elsevier.com/copyright">http://www.elsevier.com/copyright</a>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <a href="http://www.elsevier.com/permissions">http://www.elsevier.com/permissions</a>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <a href="http://www.elsevier.com/permissions">http://www.elsevier.com/permissions</a>.

## For open access articles

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <a href="http://www.elsevier.com/OAauthoragreement">http://www.elsevier.com/OAauthoragreement</a>). Permitted reuse of open access articles is determined by the author's choice of user license (see <a href="http://www.elsevier.com/openaccesslicenses">http://www.elsevier.com/openaccesslicenses</a>).

#### Retained author rights

As an author you (or your employer or institution) retain certain rights. For more information on author rights for:

Subscription articles please see

http://www.elsevier.com/journal-authors/author-rights-and-responsibilities.

Open access articles please see http://www.elsevier.com/OAauthoragreement.

## Role of the Funding Source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. If the funding source(s) had no such involvement then this should be stated. All sources of funding should be declared as an acknowledgment at the end of the text. Please see <a href="http://www.elsevier.com/funding">http://www.elsevier.com/funding</a>.

## Funding Body Agreements and Policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <a href="http://www.elsevier.com/fundingbodies">http://www.elsevier.com/fundingbodies</a>.

US National Institutes of Health (NIH) voluntary posting (" Public Access") policy.

Elsevier facilitates author response to the NIH voluntary posting request (referred to as the NIH "Public Access Policy"; see <a href="http://www.nih.gov/about/publicaccess/index.htm">http://www.nih.gov/about/publicaccess/index.htm</a>) by posting the peer-reviewed author's manuscript directly to PubMed Central on request from the author, 12 months after formal publication. Upon notification from Elsevier of acceptance, we will ask you to confirm via e-mail (by e-mailing us at NIHauthorrequest@elsevier.com ) that your work has received NIH funding and that you intend to respond to the NIH policy request, along with your NIH award number to facilitate processing. Upon such confirmation, Elsevier will submit to PubMed Central on your behalf

a version of your manuscript that will include peer-review comments, for posting 12 months after formal publication. This will ensure that you will have responded fully to the NIH request policy. There will be no need for you to post your manuscript directly with PubMed Central, and any such posting is prohibited.

## Open access

This journal offers authors a choice in publishing their research:

#### Open access

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or their research funder

#### Subscription

- Articles are made available to subscribers as well as developing countries and patient groups through our access programs (http://www.elsevier.com/access)
- No open access publication fee

All articles published open access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

**Creative Commons Attribution (CC BY)**: lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

**Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA)**: for noncommercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)**: for noncommercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

To provide open access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published open access.

Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The open access publication fee for this journal is **\$2200**, excluding taxes. Learn more about Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing.

## Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (http://webshop.elsevier.com/languageediting/) or visit our customer support site (http://support.elsevier.com) for more information.

#### Submission

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail. http://ees.elsevier.com/tiv

## Questions about submission may be directed to the appropriate editor.

Americas and Canada: daniel.acosta@uc.edu

Europe: b.blaauboer@uu.nl

All other areas of the world: daniel.dietrich@uni-konstanz.de

#### Revised versions

The medium of submission for revised papers is electronic, through the Elsevier website (http://ees.elsevier.com/tiv). Figures should be submitted as original high quality files of a standard graphics program. Revised versions should be returned within 3 months of the first date of decision. Failure to do so will result in any resubmission being treated as a new version and will therefore carry a new date of receipt.

#### Referees

The Editors require submissions by the authors of the names and addresses of 4 potential reviewers for this submission. The institutional address and e-mail address are required. At least 2 of the referees should be from a different country to the corresponding author's. The Editors reserve the right to use these or other reviewers.

#### **PREPARATION**

#### **NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

#### References

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

## Formatting requirements

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

Please ensure the text of your paper is double-spaced – this is an essential peer review requirement.

## Figures and tables embedded in text

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file.

## REVISED SUBMISSIONS

Use of word processing software

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <a href="http://www.elsevier.com/guidepublication">http://www.elsevier.com/guidepublication</a>). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

## **Manuscript Format**

Manuscripts should be written in clear and concise English; incomprehensible submissions will be returned to authors for revision. All pages must be numbered, including the Title Page, which should carry the title of the paper, the surnames and initials of the authors, and the names and address of the institutions where the work was done (with the affiliation of each author clearly indicated). Titles consisting of declarative or interrogative sentences are not acceptable. Please do not add line numbering to your source file as this will be added automatically by the EES system upon building of the PDF.

#### Introduction

Introduction: A concise and clear statement on the background, purposes and significance of the work.

## Material and methods

Materials and Methods: A detailed description of the experimental design and of any new or improved methods. Well-established methods and techniques may be identified by reference only.

#### Results

Results: Presented concisely with the aid of tables or figures where appropriate. Duplication between this section and the Discussion must be avoided.

#### **Discussion**

Discussion: A succinct interpretation of the data. Extensive literature reviews and highly speculative comments are discouraged.

# Essential title page information

- *Title.* Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Each author's academic or professional qualifications should also be listed. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name, and, if available, the e-mail address of each author.
- Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that telephone and fax numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address.
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a "Present address" (or "Permanent address") may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

#### Ahstract

Abstract: A self-contained summary of the objectives, results and significance of the study, not exceeding 200 words. Uninformative sentences such as "the significance of the results is discussed" are not acceptable.

## Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of  $531 \times 1328$  pixels (h × w) or proportionally more. The image should be readable at a size of  $5 \times 13$  cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See http://www.elsevier.com/graphicalabstracts for examples.

Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images and in accordance with all technical requirements: Illustration Service.

## Highlights

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, or, maximum 20 words per bullet point). See <a href="http://www.elsevier.com/highlights">http://www.elsevier.com/highlights</a> for examples.

## Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

#### **Abbreviations**

Abbreviations should be used sparingly. Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

## **Acknowledgements**

Acknowledgements: Providing recognition of sources of funding and donations of materials, and including any thanks the authors may wish to accord for advisory, technical or other assistance, since authorship should be limited to those who have made a major contribution to the study and to the preparation of the paper. Authors are advised to obtain approval for the wording of any acknowledgement from those whose help is noted.

## Nomenclature

The metric system is the standard for all measurements. Test chemicals and enzymes must be clearly identified, wherever possible, with the aid of CAS Registry and EC numbers.

## **Database linking**

Elsevier encourages authors to connect articles with external databases, giving their readers oneclick access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See http://www.elsevier.com/databaselinking for more information and a full list of supported databases.

#### Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

#### **Artwork**

Electronic artwork

General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files. A detailed guide on electronic artwork is available on our website:

http://www.elsevier.com/artworkinstructions.

# You are urged to visit this site; some excerpts from the detailed information are given here. Formats

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

#### Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

#### Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. For further information on the preparation of electronic artwork, please see <a href="http://www.elsevier.com/artworkinstructions">http://www.elsevier.com/artworkinstructions</a>.

Please note: Because of technical complications that can arise by converting color figures to 'gray scale' (for the printed version should you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.

#### Figure captions

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

#### **Tables**

Tables should be intelligible without reference to the text and should be planned to fit the page size of the Journal. The same data may not be reproduced in both a table and a figure. Each table must have a title and on each column there should be a heading that clearly identifies the data therein. Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

#### Reference links

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

#### Reference management software

This journal has standard templates available in key reference management packages EndNote (http://www.endnote.com/support/enstyles.asp) and Reference Manager (http://refman.com/support/rmstyles.asp). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

## Reference formatting

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

## Reference style

*Text:* All citations in the text should refer to:

- 1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;
- 2. Two authors: both authors' names and the year of publication;
- 3. *Three or more authors:* first author's name followed by 'et al.' and the year of publication. Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.

Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer et al. (2010) have recently shown ....'

List: References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

Examples:

Reference to a journal publication:

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. J. Sci. Commun. 163, 51–59.

Reference to a book:

Strunk Jr., W., White, E.B., 2000. The Elements of Style, fourth ed. Longman, New York.

Reference to a chapter in an edited book:

Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S., Smith, R.Z. (Eds.), Introduction to the Electronic Age. E-Publishing Inc., New York, pp. 281–304.

#### Video data

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <a href="http://www.sciencedirect.com">http://www.sciencedirect.com</a>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <a href="http://www.elsevier.com/artworkinstructions">http://www.elsevier.com/artworkinstructions</a>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

## **AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <a href="http://www.elsevier.com/audioslides">http://www.elsevier.com/audioslides</a>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

## Supplementary data

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <a href="http://www.sciencedirect.com">http://www.sciencedirect.com</a>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <a href="http://www.elsevier.com/artworkinstructions">http://www.elsevier.com/artworkinstructions</a>.

#### Submission checklist

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Telephone

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)

Printed version of figures (if applicable) in color or black-and-white

- Indicate clearly whether or not color or black-and-white in print is required.
- For reproduction in black-and-white, please supply black-and-white versions of the figures for printing purposes.

For any further information please visit our customer support site at http://support.elsevier.com.

#### **AFTER ACCEPTANCE**

# Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

http://dx.doi.org/10.1016/j.physletb.2010.09.059

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

## **Proofs**

One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 9 (or higher) available free from http://get.adobe.com/reader. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: http://www.adobe.com/products/reader/tech-specs.html.

If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

#### **Offprints**

The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on ScienceDirect. This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (http://webshop.elsevier.com/myarticleservices/offprints). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (http://webshop.elsevier.com/myarticleservices/booklets).

## **AUTHOR INQUIRIES**

You can track your submitted article at http://help.elsevier.com/app/answers/detail/a\_id/89/p/8045/. You can track your accepted article at http://www.elsevier.com/trackarticle. You are also welcome to contact Customer Support via http://support.elsevier.com.

© Copyright 2014 Elsevier | http://www.elsevier.com